Detecting and genotyping high-risk human papillomavirus among male patients during 2015-2023 in Beijing, China

Emerg Microbes Infect. 2024 Dec;13(1):2313848. doi: 10.1080/22221751.2024.2313848. Epub 2024 Feb 13.

Abstract

Few studies focused on human papillomavirus (HPV) in male patients. This study aimed to explore the detection rate and genotyping of HPV among male patients in Beijing to provide a reference for formulating prevention strategies for HPV infection. The cross-sectional study was conducted in Beijing Chaoyang Hospital from November 2015 to March 2023. It covered male patients from the urology and dermatology departments. Fifteen high-risk HPV genotypes were detected by the multiplex real-time polymerase chain reaction method. The overall detection rate of HPV was 25.19% (1288/5114, 95% confidence interval [CI] 24.00%-26.38%), of which the single infection rate was 16.99% (869/5114, 95% CI 15.97%-18.05%) and the co-infection rate was 8.19% (419/5114, 95% CI 7.46%-8.98%). The detection rate of HPV was 40.77% (521/1278), 35.58% (58/163), 32.69% (101/309), 31.91% (60/188), 12.63% (299/2367), and 32.35% (131/405) among male patients with balanitis, warts, rash, urethritis, prostatitis, and other urinary inflammation, respectively (P < 0.001). The top five HPV genotypes were HPV-52, HPV-58, HPV-16, HPV-51, and HPV-66. After the first positive HPV test, the proportion of male patients who turned negative was 22.47% within 3 months, 26.40% within 3-6 months, 24.72% within 6-12 months, 17.98% within 12-24 months, and 8.43% more than 24 months. The detection rate of HPV was high among male patients from the urology and dermatology departments in Beijing, which should be considered to develop HPV vaccines with better prevention effects.

Keywords: China; Human papillomavirus; genotype; male; urology.

MeSH terms

  • Beijing / epidemiology
  • China / epidemiology
  • Cross-Sectional Studies
  • Genotype
  • Human Papillomavirus Viruses
  • Humans
  • Male
  • Papillomaviridae / genetics
  • Papillomavirus Infections* / diagnosis
  • Papillomavirus Infections* / epidemiology
  • Papillomavirus Infections* / prevention & control
  • Prevalence

Grants and funding

This work was supported by National Natural Science Foundation of China [grant number 82302551], Beijing Natural Science Foundation [grant number 7234369], the Joint Research Fund for Beijing Natural Science Foundation and Haidian Original Innovation [grant number L222029, L202007 and L222028]; Fundamental Research Funds for the Central Universities and Peking University Health Science Center [grant number BMU2021YJ041]; Peking University Medicine Fund of Fostering Young Scholars’ Scientific and Technological Innovation [grant number BMU2021PY005].